¿Diabetes post COVID-19?

• Nereida Valero Cedeño Universidad Estatal del Sur de Manabí, Ecuador https://orcid.org/0000-0003-3496-8848

DOI: https://doi.org/10.54817/IC.v63n1a00

Abstract

The appearance of Diabetes Mellitus (DM) in patients who have suffered from COVID-19 could be added, if confirmed by subsequent studies, to the long list of consequences caused by this pandemic. Likewise, the impact of COVID-19 on the endocrine system is poorly studied. Previous coronavirus out-breaks, as well as other previously reported viral infections, have been associated with new onset DM. However, there is little research in this regard and the question arises again as to how viruses can contribute to the onset of the disease or if they modify factors that ultimately trigger the lack of control of blood glucose, together with insulin resistance (IR). The recent COVID-19 pandemic has made it abundantly clear that DM increases the risk of more frequent and severe viral infections. At the same time, proinflammatory cytokines promote IR and constitute a risk factor for the development of DM. This raises the existence of a reciprocal and harmful interaction between the immune and endocrine systems in the context of DM. It is not clear why these two systems would interact by inducing transient changes in systemic metabolism as a strategy against viral infection. In people with DM, this system fails, negatively affecting the antiviral immune response. In addition, immune-mediated changes in systemic metabolism after infection may worsen glycemic control, laying the groundwork for future research.

References

Stidsen JV, Henriksen JE, Olsen MH, Thomsen RW. Nielsen JS, Rungby J, Sinna P Ulrichsen SP, Berencsi K, Kahlert JA, Friborg SG, Brandslund I, Nielsen AA, Christiansen JS, Sørensen HT, Olesen TB, Beck-Nielsen H. Pathophysiology-based phenotyping in type 2 diabetes: A clinical classification tool. Diabetes Metab Res Rev 2018; 34:e3005. https://doi.org/10.1002/ dmrr.3005.

Wagner R, Heni M, Tabák AG, Machann J, Schick F, Randrianarisoa E, Fritsche A. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nature Medicine 2021; 27(1): 49-57. https://doi.org/10.1038/s41591-020-1116-19.

Nyunt TPK, Mullol J, Snidvongs K. Immune response to fungi in diabetic patients with invasive fungal rhinosinusitis. Asian Pac J Allergy Immunol 2020; 38(4):233-238. Doi: 10.12932/ AP-080620-0874.

Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, Cooper ME, Chai Z, Del Prato S, Ji L, Hopkins D, Herman WH, Khunti K, Mbanya JC, Renard

E. New-Onset Diabetes in Covid-19. N Engl J Med 2020; 383(8):789-790. Doi: 10.1056/NE- JMc2018688.

Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab 2021; 23(3):870-874. Doi: 10.1111/dom.14269.

Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis 2021; 40(5):905-919. Doi: 10.1007/s10096-020-04138-6.

Molina DI, Muñoz TM, Guevara K. Inhibidores de la enzima convertidora de angiotensina y bloqueadores de los receptores de angiotensina II: ¿aumentan el riesgo de padecer COVID-19? Rev Colom Cardiol 2020: 27(3): 132-136. https://doi.org/10.1016/j.rccar.2020.05.003.

Ata A, Jalilova A, Kırkgöz T, Işıklar H, Demir G, Altınok YA, Özkan B, Zeytinlioğlu A, Darcan Ş, Özen S, Gökşen D. Does COVID-19 predispose patients to type 1 diabetes mellitus? Clin Pediatr Endocrinol 2022; 31(1):33-37. Doi: 10.1297/cpe.2021-0050.

Suwanwongse K, Shabarek N. Newly diagnosed diabetes mellitus, DKA, and COVID-19: Causality or coincidence? A report of three cases. J Med Virol 2021; 93(2):1150-1153. Doi: 10.1002/jmv.26339.

Duntas LH, Jonklaas J. COVID-19 and thyroid diseases: A bidirectional impact. J Endocr Soc 2021;5(8):bvab076. doi: 10.1210/jendso/bvab076.

Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)- Potsdam Study. Diabetes 2003; 52(3):812-7. Doi: 10.2337/diabetes.52.3.812.

Bender C, Rajendran S, von Herrath MG. New insights into the role of autoreactive CD8 T cells and cytokines in human Type 1 diabetes. Front Endocrinol (Lausanne) 2021;11:606434. Doi: 10.3389/fendo.2020.606434.

Katsogiannos P, Kamble PG, Pereira MJ, Sundbom M, Carlsson PO, Eriksson JW, Espes D. Changes in circulating cytokines and adipokines after RYGB in patients with and without Type 2 diabetes. Obesity 2021; 29(3):535-542. Doi: 10.1002/oby.23093.

Valero Cedeño NJ, Vélez Cuenca MF, Duran Mojica AA, Torres Portillo M. Afrontamiento del COVID-19: estrés, miedo, ansiedad y depresión? Enferm Inv 2020;5(3):63-70. http://dx.doi. org/10.31243/ei.uta.v5i3.913.2020.

Guarnotta V, Ferrigno R, Martino M, Barbot M, Isidori AM, Scaroni C, Ferrante A, Arnaldi G, Pivonello R, Giordano C. Glucocorticoid excess and COVID-19 disease. Rev Endocr Metab Disord 2021; 22(4):703-714. Doi: 10.1007/s11154-020-09598-x.